Immunotherapy of Lung Adenocarcinoma Patient with Peptide-Pulsed Dendritic Cells: a Case Report

Abstract

Immunotherapy with ex vivo generated dendritic cells (DCs) is reported to be of low toxicity and of diverse effectiveness in cancer treatment. The synthetic antigens are frequently used for immunotherapy especially for patients with stable disease after prior treatment. We described the effect of peptide-loaded DCs-based immunotherapy on patient with recurrent surgically resected adenocarcinoma with bronchoalveolar feature with co-existing of Takayasu arteritis and chronic hepatitis B. In January 2010, 61-year-old patient received subcutaneously four bi-weekly vaccinations of DCs loaded with MUC1 and MAGE-3 epitopes. Additionally, he received three bi-weekly booster vaccinations after 7 months from the first course of immunotherapy. Delayed-type hypersensitivity test was positive only for MAGE-3 antigen. The evidence expansion of MAGE-3-specific CD8(+) cells after first vaccination and after third vaccination during boosters injections was observed (from 0.08% before vaccination to 0.5% after first vaccination; from 0.05% before booster vaccination to 0.24% after third injection). Computed tomography scans performed after first course and after booster course of vaccination until April 2011 did not shown any presence of lung tumour or metastases. Based on clinical factors (no completed wedge-resection and recurrent character of cancer) as well as on the presence of the tumour-antigen-specific immunological response, we could speculated that immunotherapy prolonged disease free-survival in our patient. Over 16 months from first vaccination, the patient remains without symptoms of cancer.

Tolerogenic Dendritic Cells Reduce Airway Inflammation in a Model of Dust Mite Triggered Allergic Inflammation

“…This result may be explained by the fact that our cells were maintained longer in the presence of dexamethasone as the treatment for 1 hour is related to an in vivo instability of these cells, 47 while treatment for 48 hours produced better results in terms of inhibiting IFN-γ production by effector lymphocytes than a 6-hour treatment. 48 This effect in down-regulating IFN-γ was also observed after injection of TolDCs generated here, favoring the hypothesis that action of these cells is mainly systemic, affecting immune responses in peripheral lymphoid organs, since they were transplanted before allergy induction. In fact, Floderer et al 26 demonstrated that the subcutaneous immunization of wild-type mice with DCs affects the cytokine microenvironment in the spleen, causing T-cell phenotype reprogramming.…”

CYLD expression in dendritic cells involved in the immunoregulation of pulmonary adenocarcinoma via NF-κB pathway

“…Studies showed that the B cell and CD8 þ T cell, CD3 þ and FOXP3 þ T cells infiltration were significantly relative with the prognostic value in lung adenocarcinoma [25,26]. Moreover, DCs was also reported to be contributed to the immunotherapy of patient with lung adenocarcinoma [27]. Our previous study also showed that IL33 repressed the progression of PA via the regulation on DCs.…”

The antitumor effect of human cord blood-derived dendritic cells modified by the livin α gene in lung cancer cell lines

“…When DC vaccines are administered either simultaneously with or sequentially in combination with other anticancer agents, they can induce synergistic antitumor activity while minimizing the toxicity to normal hematopoietic or other organs (47)(48)(49). There are several methods to load DCs with tumor antigens.…”